Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy

Rutika Mehta, Anand Shah, Khaldoun Almhanna

Abstract: Gastric and esophageal cancers account for the six most common causes of cancer death worldwide. Locally advanced resectable cancers have a 5-year life expectancy of 30%. Despite use of chemotherapy, median overall survival for stage IV cancer rarely exceeds 1 year. A subset of gastric cancers such as microsatellite-instable tumor and Epstein–Barr virus-positive tumors have a rich immune infiltrate that makes them more responsive to immune-directed therapies. Tumors can evade T-cell-mediated ‘immune surveillance’ by activating the programmed cell death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway. Targeting PD-1 and thus de-engaging them from its ligands can help restore immunogenicity. Pembrolizumab is the first immunotherapy to be approved by US FDA for PD-L1 expressing gastric and gastroesophageal junction (GEJ) cancers after they have progressed on at least two prior lines of treatment. While PD-L1 positivity does not define tumor’s responsiveness to pembrolizumab, PD-L1-positive tumors have better overall response rates. The treatment is usually well tolerated and has a favorable adverse events profile. The exact setting for use of pembrolizumab remains to be determined. Pembrolizumab failed to improve overall survival when administered as second-line treatment for advanced, metastatic gastric and GEJ cancers. There are several ongoing studies with various combinations and different settings not only with pembrolizumab but also with other checkpoint inhibitors.

Keywords: gastric cancer, gastroesophageal junction cancer, pembrolizumab, PD-1

Introduction

Gastric and esophageal cancers are the fifth and eighth most common cancers occurring worldwide, respectively. They are also among the top six cancers for mortality, accounting for over 1.1 million deaths worldwide in 2012. In the US alone, a little over 43,000 new cases and 26,650 deaths are expected to occur due to gastric and esophageal cancers in 2018. There is significant geographical variation in the incidence of gastric and gastroesophageal junction (GEJ) cancers worldwide. The incidence rates of gastric cancers are highest in parts of Eastern Europe, Iran, Russia, many parts of Central and South America, and several countries of East Asia. Gastric adenocarcinoma accounts for the most common histological subtype of gastric cancers (~95%), others being lymphomas, neuroendocrine tumors, and mesenchymal tumors. Adenocarcinomas are the most common histological subtype of GEJ cancers (90%). In the US, the incidence of noncardia gastric cancers have declined significantly over the past four decades. However, during this same time, the incidence of GEJ adenocarcinomas (GEJAC)
has steadily increased. These are four times as common in Whites than in Blacks and also more common among males than among females. The rise in the incidence of GEJAC is being attributed to increased incidence of gastroesophageal reflux disease and obesity. In spite of improvements in multidisciplinary diagnostic and treatment modalities, the prognosis of GEJ and gastric cancers remains poor. While localized disease achieves 5-year survival rates of 45% and 68% in esophageal and gastric cancers, respectively, the 5-year survival rates for advanced disease with either cancers approach only ~5%. Combination of platinum compounds such as cisplatin or oxaliplatin with fluoropyrimidines such as 5-fluorouracil (5-FU) or capecitabine remains the mainstay of standard first-line therapy for gastric cancer improving overall survival (OS) to about 9–11 months. Therefore, there is a need for targeted treatments and pathway-driven treatments for advanced gastric cancer. The first targeted therapy to be approved for gastric cancer was trastuzumab based on significant improvement in OS from 11 months to 13.8 months (P = 0.046) with the addition of trastuzumab to 5-FU and cisplatin as first-line treatment in patients with advanced cancer whose cancer overexpressed HER-2neu. The next targeted therapy to be approved for gastric cancer was ramucirumab, which was initially given as single agent in April 2014 and then in combination with paclitaxel in November 2014 after the success of two landmark trials REGARD and RAINBOW that demonstrated improvement in OS of gastric cancer patients who have previously been treated with a fluoropyrimidine-based therapy. Ramucirumab showed an absolute OS benefit of 1.3 months over placebo as single agent and 2.2 months in combination with paclitaxel over paclitaxel alone, with OS benefit being statistically significant in both studies. Other treatments directed against HER-2neu overexpression, mesenchymal epithelial transition factor, epidermal growth factor receptor, and vascular endothelial growth factor have not shown improvement in OS in gastric cancer patients across several trials.

In a recent molecular classification performed by The Cancer Genome Atlas (TCGA), four subtypes have been proposed. Although correlation to clinical data was not made and therefore prognostic differences cannot be ascertained, some gastric cancers were distinctly found to have multiple DNA alterations that might result in increased neoantigens (mismatch repair deficiency or microsatellite instability-high [MSI-H]) and as such sensitive to immune modulators such as checkpoint inhibitors. In recent years, emergence of immune-checkpoint inhibitors has revolutionized the management of solid tumors. Checkpoint inhibitors targeting programmed cell death receptor 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have led to improved response rates and OS across several tumor types. In many cases, these responses are characterized by their durability and a favorable adverse effect profile. In September 2017, the US FDA approved pembrolizumab (Merck & Co., Kenilworth, NJ, USA) for the third-line treatment of advanced PD-L1-positive GEJ tumor. This approval was based upon tumor response rates and durability of response as reported in the KEYNOTE-059 Phase II trial. This review will discuss the pharmacology, safety, and efficacy of pembrolizumab in the treatment of gastric and GEJ tumors.

Immune landscape of gastric and GEJ cancers

The mechanism by which cancer cells including gastric and GEJ cancers are kept in check and prevented from developing is called “immune surveillance”, whereby the immune cells destroy cancer cells after recognition of tumor-specific antigens, before they can cause harm. If this elimination is incomplete, there is a state of equilibrium during which time the tumor may develop and accumulate DNA mutations or remain dormant. If the immune system is yet not able to completely eliminate the tumor cells, then this mechanism is called “immune escape”. Activated cytotoxic T cells (CTLs) assist in immune surveillance. Tumor infiltrating lymphocytes (TILs) when found such as in colon and gastric cancers portend a good prognosis. TILs by utilizing perforins and granzymes kill tumor cells via direct and indirect mechanisms. The tumor microenvironment has immunosuppressive network that exhausts the CTL/TIL leading to T-cell dysfunction. The antigen recognition by CTLs induced PD-1 expression and upon interaction with its ligand, programmed death ligand-1 (PD-L1), T-cell function is inhibited and is proposed as one of the mechanisms of “immune escape” by cancer.

TCGA performed a comprehensive analysis of 295 primary tumor samples from patients with untreated gastric adenocarcinoma, using whole-exome sequencing, somatic copy number analysis, DNA methylation profiling, mRNA sequencing, microRNA sequencing, and reverse phase protein array. The four molecular subtypes identified were as follows: 1) Epstein–Barr virus (EBV)-positive (9%), 2) microsatellite instability-high (MSI-H) (22%), 3) genomically stable (20%), and 4) chromosomal instability (CIN) (50%). The EBV-positive tumors showed a high frequency of DNA hypermethylation as well as amplifications of JAK-2, PD-L1, and PD-L2. Unlike the EBV-positive
tumors, the MSI-H tumors have MLH1 silencing as a result of methylation. About 40% of gastric and GEJ cancers are PD-L1 positive. PD-L1 positivity is more frequent in EBV-positive and MSI-H tumors. Among EBV-positive cancers, PD-L1 staining is observed not only in 50% of tumor cells but also in 94% of infiltrating immune cells. Similarly, among MSI-H tumors, 33% and 45% of tumor cells and immune cells are stained positive for PD-L1, respectively. Thus, both these subtypes of gastric cancers are considered to have a rich immune infiltrate and therefore more responsive to checkpoint inhibitors.

Studies have shown that tumors with frequent somatic mutations have higher immune signatures than tumors with lower somatic mutations but high copy number alterations. These low immune signature cancers also correlated with CIN. Some high immune signature cancers include lung adenocarcinoma, melanoma, or kidney cancer, all of which have shown superior responses to immunotherapy. As noted above, a majority of gastric cancers are CIN which correlates with low immune signatures and possibly lower responses to immunotherapeutic agents.

Pembrolizumab in gastric and GEJ cancers

Pharmacology and mechanism of action

Pembrolizumab (Keytruda®; MK-3745) is a humanized, highly selective IgG4 kappa isotype monoclonal antibody against PD-1. Its molecular weight is 149 kDa. As outlined earlier, PD-1 is expressed in activated T cells, while its ligands PD-L1 and PD-L2 are frequently overexpressed in some tumors. When PD-1 engages with its ligands on tumor cells, the activated pathways send inhibitory signals to T cells, thus disrupting its function of immune surveillance and in turn promote tumor growth. Pembrolizumab, by binding to PD-1, prevents its interaction with PD-1 ligands, thus releasing the inhibitory response of the immune response (Figure 1).

Pharmacokinetics

Pembrolizumab is a fully humanized IgG monoclonal antibody; therefore, it follows pharmacokinetics (PK) similar to that of endogenous IgG. Its volume of distribution (VD) is 6 L, which is similar to that of plasma volume. Despite the small VD, pembrolizumab is distributed to peripheral tissues by paracellular and/or transcellular movement following parenteral dosing. The drug is eliminated by both target-mediated (linear) and constant region-mediated (nonlinear) routes. Terminal half-life is 22 days. A recent study evaluated population-based PK of pembrolizumab at various doses. This included patients receiving pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks and 3 weeks as well as 200 mg flat dose every 3 weeks. This study found that weight-based dose and fixed dose were appropriate for pembrolizumab and neither regimen provided a PK advantage over the other. Pembrolizumab does not require dose adjustment for mild, moderate, or severe renal impairment and mild hepatic impairment. There is insufficient data to determine whether pembrolizumab clearance is impacted in a clinically meaningful way in patients with moderate to severe hepatic impairment. In addition, age, sex, and race do not have clinically important effects on pembrolizumab clearance.

Clinical studies

The very first indication of efficacy of checkpoint inhibitors in MSI-H advanced cancers refractory to prior systemic treatment was demonstrated in a Phase II clinical trial led by Le et al (NCT01876511). Eighty-six patients with MSI-H colorectal cancers (CRC) and MSI-H non-CRCs including five patients with gastroesophageal tumors were enrolled. Pembrolizumab 10 mg/kg of body weight was administered intravenously every 14 days. The objective response rate (ORR) in MSI-H gastroesophageal tumors was 60% similar to that observed for CRC (52%), with three of the five patients achieving complete response (CR). Two Phase I b studies of single agent pembrolizumab in advanced solid tumors have provided us with safety data in previously treated PD-L1-positive advanced or metastatic cancers.

KEYNOTE-012

This is a multicenter, open-label, Phase Ib study of single agent pembrolizumab that included patients with advanced cancer.
or metastatic gastric cancer, urothelial cancer, triple-negative breast cancer, and head and neck cancer. The gastric cancer cohort included recurrent or metastatic PD-L1-positive gastric or GEJ adenocarcinomas with no limit on number of prior treatment. Positivity was defined as >1% of tumor and/or contiguous mononuclear inflammatory cells (using Dako Assay, 22C3 antibody). Thirty-nine patients from centers across USA, Japan, Israel, South Korea, and Taiwan were included in the gastric cohort with similar numbers from Asia vs rest of the world. Patients received pembrolizumab at 10 mg/kg intravenously every 2 weeks. The median age was 63 years with majority (72%) being males. Four (10%) patients were treatment naïve, while 67% had received two or more prior lines of systemic treatment. Of the 24 patients for whom MSI status was available, 4 (17%) were noted to be MSI-H. The median follow-up duration was 10.8 months with 85% (33 patients) discontinuing treatment (32 due to progressive disease and 1 due to treatment-related adverse events [AEs]). Thirty-six patients were evaluable for response and the confirmed ORR was 22% [95% CI 10–39] (eight patients). There were no CRs. Time to response was 2 months, with median duration of response being 9.2 months. The median progression-free survival (PFS) was 1.9 months (95% CI 1.8–3.5) and median OS was 11.4 months (95% CI 5.7–not reached). In terms of PD-L1 positivity, patients were evaluated for PD-L1 staining based on the previously developed prototype assay at the time of screening and then based on the clinical trial assay as well. Unfortunately, discordant results were noted between these two PD-L1 tests. Interestingly, based on tumor proportion score (TPS), tumors with TPS of 0 has 24% ORR and tumors with TPS ≥1 had 17% ORR.32

KEYNOTE-028
This is a non-randomized, multi-center, open-label, Phase Ib study of single agent pembrolizumab including PD-L1-positive 20 different tumor subtypes that enrolled patients from USA, UK, France, Japan, Korea, and Taiwan. Twenty-three patients with esophageal cancer were included in the study. Patients were treated with pembrolizumab at 10 mg/kg intravenously every 2 weeks up to 2 years. The median age was 65 years, majority were men (83%), and 78% were of squamous cell histology. More than half had received prior radiation treatment and 87% had received two or more prior lines of treatment. The median duration of follow-up was 7 months and majority (91%) had treatment discontinuation due to progressive disease (57%) or AEs (9%). The ORR was 30% (95% CI 13%–53%). The ORR for adenocarcinomas was superior (40%) than that for squamous cell carcinomas (28%). Median time to response was 4 months, with duration of response being 15 months. The median PFS was 1.8 months (95% CI 1.7–2.9 months) and median OS was 7 months (95% CI 4.3–17.7 months).31

In both studies, KEYNOTE-012 and KEYNOTE-028, a six-gene (CXCL9, CXCL10, IDO1, IFNG, HLA-DRA, and STAT4) interferon-γ-related signature was evaluated and correlated with ORR and PFS. However, in both these studies, the gene signature could not predict the response for pembrolizumab in these cohorts.

KEYNOTE-059
KEYNOTE-059, a Phase II, multicohort, single-arm trial for treatment of advanced gastric and GEJ cancers with pembrolizumab as monotherapy or in combination with chemotherapy has completed enrollment. The first cohort included patients with advanced or metastatic gastric and GEJ cancers who had received at least two prior systemic therapies and were treated with pembrolizumab 200 mg every 3 weeks. Cohort 2 assessed the combination of pembrolizumab 200 mg every 3 weeks in combination with 5-FU and cisplatin as first-line treatment for advanced gastric and GEJ cancers, while cohort 3 assessed pembrolizumab monotherapy as first-line treatment in the same population. Cohort 3 included only PD-L1-positive tumors. The PD-L1 positivity rates were 57% and 64% in cohorts 1 and 2, respectively.

Cohort 1 enrolled 259 patients with recurrent or metastatic gastric or GEJ adenocarcinomas across 16 countries irrespective of PD-L1 status. The median age was 62 years with majority being males (76.4%). Fifty-two percent patients had received two or more prior therapies for metastatic disease. More than half of the patients (57.1%) were PD-L1 positive. The median duration of follow-up was 5.8 months, with about 90% discontinued treatment mostly due to progressive disease. The ORR was 11.6% (95% CI 8.0%–16.1%) with CR in 2.3% (95% CI 0.9%–5.0%) of the entire study population. Median time to response was 2.1 months, with median duration of response being 8.4 months. Median PFS was 2.0 months (95% CI 2.0–2.1) and median OS was 5.6 months (95% CI 4.3–6.9). Among PD-L1-positive tumors, ORR was 15.5% as compared to 6.4% in PD-L1-negative tumors. Response rates were superior when pembrolizumab was used as third-line treatment as compared to that when used as fourth or further line of treatment (16.4% vs 6.4%). Seven of the evaluable tumors were MSI-H and the ORR was 57.1% as compared to non-MSI-H tumors (9.0%).32 Based on this favorable data and good response rates in third-line

...
setting, US FDA approved the use of pembrolizumab in PD-L1-positive gastric and GEJ adenocarcinomas after progression on two prior lines of treatment in September 2017.34

Cohort 2 with HER-2neu-negative advanced gastric and GEJ adenocarcinoma patients treated with pembrolizumab in combination with 5-FU and cisplatin as first-line treatment enrolled 25 patients. The median age was 64 years with 64% males. While in cohort 1, GEJ and gastric cancer cases were balanced, cohort 2 had a majority of gastric adenocarcinomas (80%). PD-L1 positivity rate was 64%. The ORR was 60% (95% CI 39%–79%) with 4% CR (95% CI 0%–20%). In PD-L1-positive patients, the ORR was 68.8% (95% CI 41%–89%), while it was 37.5% (95% CI 9%–76%) in PD-L1-negative patients.13 The CR rate was 0% (95% CI 0%–22%) and 13% (95% CI 0%–53%) in PD-L1-positive and PD-L1-negative patients, respectively. The median follow-up was 13.8 months, with duration of response being 4.6 months. The median PFS was 6.5 months (95% CI 5.9–10.6 months) and median OS was 13.8 months (95% CI 8.6 months—not reached). These encouraging results have led to the conception of Phase III trial KEYNOTE-062 that is currently ongoing.

Preliminary results from cohort 3 were presented at European Society for Medical Oncology 2017. Thirty-one patients were enrolled with median age 62 years and more than half (61%) being male patients. The majority were gastric adenocarcinomas (61%) and all patients were HER-2neu negative and PD-L1 negative. The ORR for this cohort was 25.8% (95% CI 12%–45%) with 7% CR (95% CI 1%–21%). The median follow-up was 17.5 months and duration of response was 9.6 months. The median PFS was 3.3 months (2.0–6.0 months) and median OS was 20.7 months (9.2–20.7 months).36

Other studies

A Phase III randomized, open-label clinical trial (KEYNOTE-061) assessing single agent pembrolizumab vs paclitaxel in PD-L1-positive advanced, metastatic gastric and GEJ adenocarcinomas (including HER-2-neu positive) after progression on first-line fluoropyrimidine and platinum doublet, failed to show OS benefit as second-line treatment in this population (HR, 0.82 [95% CI, 0.66–1.03]; P=0.042 [one-sided]).37,38 To assess the efficacy of pembrolizumab as first-line treatment in PD-L1+/HER-2-neu-negative locally advanced or metastatic gastric or GEJ adenocarcinomas, a Phase III trial (KEYNOTE-062) is currently enrolling patients in a 1:1:1 fashion to pembrolizumab monotherapy vs pembrolizumab plus 5-FU/cisplatin vs placebo plus 5-FU/cisplatin.39

Details about the characteristics and primary outcome measures of these studies are outlined in Tables 1 and 2.

Safety and tolerability

Safety of pembrolizumab in gastric and esophageal tumors has been evaluated in three studies as shown in Tables 1 and 2. Overall toxicity profile in gastric and esophageal tumors was similar to that seen in previously published studies in other advanced malignancies.40–42 Treatment interruptions and discontinuations occurred at higher rates in patients receiving 10 mg/kg dose than in those receiving 200 mg flat dose. Details of treatment-related AEs are outlined in Table 3.

The immune-related AEs (nine patients, 23%) noted in KEYNOTE-012 were mostly grade 1 or grade 2 thyroid disorders (hypothyroidism or hyperthyroidism) and also one grade 4 pneumonitis.32 In KEYNOTE-028, the immune-related AEs were noted in six patients (26%) and included hypothyroidism, enterocolitis, adrenal insufficiency, generalized rash, and hyperthyroidism.31 In cohort 1 of KEYNOTE-059 study, 46 patients (17.8%) experienced immune-related AEs, most commonly being hypothyroidism, hyperthyroidism, and colitis. Ten patients (21.7%) had their treatment interrupted because of immune-related AEs. All patients in cohort 2 of KEYNOTE-059 experienced immune-mediated or infusion-related AEs, common ones being hyperthyroidism, hypothyroidism, and rash. Twenty-five (80%) patients in cohort 3 developed immune-related AEs, common ones being pneumonitis, colitis, and rash. There was one death attributed to pneumonitis in this study.33,35,36

Quality of life (QoL) and cost-effectiveness

While long-term assessments on QoL with pembrolizumab treatment have not been made in specific gastric and GEJ adenocarcinoma population, some studies have focused on non-small-cell lung cancer (NSCLC) and urothelial cancer, favoring treatment with pembrolizumab as compared to chemotherapy. Analyses of KEYNOTE-042, a Phase III trial of pembrolizumab vs platinum doublet chemotherapy in treatment-naïve NSCLC patients, showed that baseline-to-week 15 change in European Organization for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 items (QLQ-C30) Global Health Status (GHS)/QoLscore was 6.9 (95% CI 3.3–10.6) for pembrolizumab and −0.9 (−4.8 to 3.0) for chemotherapy, for a difference of 7.8 (2.9–12.8; two-sided nominal P=0.0020). Time to deterioration (TTD) was also significantly longer with pembrolizumab than with chemotherapy.43 A Health-related Quality of Life (HRQoL) analysis of KEYNOTE-045 study comparing
### Table 1 Patient and tumor characteristics for key studies assessing pembrolizumab in gastric and GEJ adenocarcinomas

<table>
<thead>
<tr>
<th>Study</th>
<th>Study status</th>
<th>Tumor type</th>
<th>Phase</th>
<th>N</th>
<th>Major sites</th>
<th>Key inclusion criteria</th>
<th>PD-L1 positive rate (%)</th>
<th>PD-L1 positive definition</th>
<th>MSI-H tumors (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KEYNOTE-012</td>
<td>Completed</td>
<td>All solid tumors. Cohort for gastric and GEJ adenocarcinomas</td>
<td>Ib</td>
<td>39</td>
<td>USA, Israel, Japan, South Korea, Taiwan</td>
<td>PD-L1-positive metastatic or recurrent tumors with no limit for number of previous therapy received</td>
<td>–</td>
<td>–</td>
<td>4 of 24 (17%)</td>
</tr>
<tr>
<td>KEYNOTE-028</td>
<td>Completed</td>
<td>All solid tumors. Cohort for SCC and adenocarcinomas of the esophagus and GEJ</td>
<td>Ib</td>
<td>23</td>
<td>France, Japan, Korea, Taiwan, UK, USA</td>
<td>PD-L1-positive metastatic or recurrent tumors with no limit for number of previous therapy received</td>
<td>–</td>
<td>–</td>
<td>NR</td>
</tr>
<tr>
<td>KEYNOTE-059</td>
<td>Completed. Updated results pending</td>
<td>Gastric and GEJ adenocarcinoma</td>
<td>II – cohort 1</td>
<td>259</td>
<td>North America, Australia, Europe, South America, Asia</td>
<td>Gastric and GEJ adenocarcinomas that have received at least two prior lines of treatment for metastatic or recurrent disease</td>
<td>57.1</td>
<td>CPS ≥ 1</td>
<td>7 of 174 (4%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cohort 2</td>
<td>25</td>
<td>Same as above</td>
<td>HER-2-neu-negative metastatic gastric and GEJ adenocarcinomas with no prior systemic treatment</td>
<td>64</td>
<td>CPS ≥ 1</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cohort 3</td>
<td>31</td>
<td>Same as above</td>
<td>PD-L1-positive, HER-2-neu-negative metastatic gastric and GEJ adenocarcinomas with no prior systemic treatment</td>
<td>100</td>
<td>CPS ≥ 1</td>
<td>–</td>
</tr>
<tr>
<td>KEYNOTE-061</td>
<td>Completed. Updated results pending</td>
<td>Gastric and GEJ adenocarcinomas</td>
<td>III</td>
<td>720</td>
<td>USA, Asia, Europe, Australia</td>
<td>Metastatic or recurrent gastric/GEJ adenocarcinomas including HER-2-neu-positive tumors that have progressed on first-line systemic therapy (should have progressed on trastuzumab-containing regimen if HER-2-neu positive)</td>
<td>Pending</td>
<td>CPS ≥ 1</td>
<td>Pending</td>
</tr>
<tr>
<td>KEYNOTE-062</td>
<td>Ongoing</td>
<td>Gastric and GEJ adenocarcinomas</td>
<td>III</td>
<td>–750</td>
<td>Same as above</td>
<td>Locally advanced or metastatic gastric or GEJ adenocarcinoma that are PD-L1+/HER-2-neu negative and not received any prior systemic therapy</td>
<td>100</td>
<td>CPS ≥ 1</td>
<td>Pending</td>
</tr>
</tbody>
</table>

**Abbreviations:** CPS, combined positive score; GEJ, gastroesophageal junction; NR, not reported; SCC, squamous cell carcinoma; MSI-H, microsatellite instability-high; PD-L1, programmed death ligand-1.
Table 2 Treatment and outcomes descriptions for key studies assessing pembrolizumab in gastric and GEJ adenocarcinomas

<table>
<thead>
<tr>
<th>Study</th>
<th>PD-L1 staining</th>
<th>Treatment</th>
<th>≥2 prior therapies (%)</th>
<th>Response rate/CR (%)</th>
<th>OS</th>
<th>PFS</th>
<th>DOR</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Overall PD-L1 positive PD-L1 negative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-012</td>
<td>22C3 antibody</td>
<td>Pembrolizumab 10 mg/kg Q2W</td>
<td>67</td>
<td>22/0</td>
<td>11.4 months</td>
<td>1.9 months</td>
<td>9.2 months</td>
</tr>
<tr>
<td></td>
<td>Expression was scored separately in tumor cells and mononuclear inflammatory cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-028</td>
<td>22C3 antibody</td>
<td>Pembrolizumab 10 mg/kg Q2W</td>
<td>87</td>
<td>30/0</td>
<td>7 months</td>
<td>1.8 months</td>
<td>15 months</td>
</tr>
<tr>
<td></td>
<td>Expression was scored separately in tumor cells and mononuclear inflammatory cells</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KEYNOTE-059</td>
<td>22C3 antibody</td>
<td>Pembrolizumab 200 mg Q3W (cohort 1)</td>
<td>51.7</td>
<td>11.6/2.3</td>
<td>5.6 months</td>
<td>2 months</td>
<td>8.4 months</td>
</tr>
<tr>
<td></td>
<td>Combined positive score ([total number of PD-L1-positive cells/ total number of tumor cells] ×100) ≥1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pembrolizumab 200 mg Q3W + cisplatin 80 mg/m² Q3W + 5-FU 800 mg/m² Q3W or capecitabine 1,000 mg/m² Q3W (cohort 2)</td>
<td>0</td>
<td>60/4 69/0</td>
<td>20.8 months</td>
<td>6.6 months</td>
<td>5 months</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pembrolizumab 200 mg Q3W (cohort 3)</td>
<td>0</td>
<td>26/7</td>
<td>20.7 months</td>
<td>3.3 months</td>
<td>9.6 months</td>
</tr>
</tbody>
</table>

Note: °PD-L1 immunohistochemistry 22C3 pharmDx (Dako, Inc.) is an US FDA-approved test for PD-L1 testing in non-small-cell lung cancer and gastric/GEJ adenocarcinomas.

Abbreviations: CR, complete response; DOR, duration of response; DOP, duration of progression; GEJ, gastroesophageal junction; OS, overall survival; PFS, progression-free survival; PD-L1, programmed death ligand-1.
Table 3 Safety and tolerability data for key studies assessing pembrolizumab in gastric and GEJ adenocarcinomas

<table>
<thead>
<tr>
<th>Study</th>
<th>Dose of pembrolizumab</th>
<th>Treatment discontinuation/ interruptions due to treatment-related AEs</th>
<th>All treatment-related AEs</th>
<th>Grade 3/4 AEs</th>
<th>Death</th>
<th>Key AEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>KEYNOTE-012</td>
<td>10 mg/kg Q2W</td>
<td>None</td>
<td>26 (67%)</td>
<td>5 (13%)</td>
<td>None</td>
<td>Fatigue, decreased appetite, hypothyroidism, pruritus, arthralgias</td>
</tr>
<tr>
<td>KEYNOTE-028</td>
<td>10 mg/kg Q2W</td>
<td>9%</td>
<td>9 (39%)</td>
<td>4 (9%). No Gr4 AEs</td>
<td>None</td>
<td>Rash/generalized rash, decreased appetite, decreased lymphocyte count</td>
</tr>
<tr>
<td>KEYNOTE-059</td>
<td>200 mg Q3W</td>
<td>C1 – 7.7%</td>
<td>156 (60.2%)</td>
<td>46 (17.8%)</td>
<td>2 (0.8%)</td>
<td>Fatigue, pruritus, rash, hypothyroidism, decreased appetite, anemia, nausea, diarrhea, arthralgia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C2 – 20%*</td>
<td>25 (100%)</td>
<td>19 (76%)</td>
<td>None</td>
<td>Neutropenia, stomatitis, anemia, decreased appetite, fatigue, HFS, thrombocytopenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C3 – none</td>
<td>24 (77%)</td>
<td>7 (23%)</td>
<td>1 (3%)</td>
<td>Neutropenia, diffuse uveal melanocytic proliferation, colitis, bile duct obstruction, dehydration, hyponatremia, rash</td>
</tr>
</tbody>
</table>

Note: *Pembrolizumab-related interruptions.

Abbreviations: AEs, adverse events; C1, cohort 1; C2, cohort 2; C3, cohort 3; Gr, grade; GEJ, gastroesophageal junction; HFS, hand-foot syndrome.

Pembrolizumab to investigator’s choice chemotherapy in previously treated urothelial cancer patients showed that pembrolizumab delayed the TTD in QoL scores as compared to chemotherapy (median 3.5 months vs 2.3 months; HR 0.72; P=0.004). When global health status/QoL scores were compared at baseline and then at 15 weeks, the mean change was 0.69 (95% CI –2.40 to 3.77) with pembrolizumab as compared to –8.36 (95% CI –11.84 to 4.89) with chemotherapy. We will have to wait for long-term data from the above trials to make these assessments for gastric and GEJ adenocarcinoma patients. Cost-effectiveness studies derived from the KEYNOTE-045 study show that the cost of pembrolizumab to gain one quality-adjusted life-year is $122,557 in the US, which is higher than the cost in other developed countries, but it is considered cost-effective only in the US because of significantly higher threshold for willingness-to-pay. Based on the studies, pembrolizumab is also considered as cost-effective, first-line treatment for NSCLC when compared to other chemotherapies that express high levels of PD-L1 with TPS ≥50%. Such studies are not yet available for gastric or GEJ cancers. While cost-benefit analyses of use of immunotherapy in gastric and GEJ cancers would be valuable information for clinicians, a detailed overview is outside the scope of this article.

Gaps in use of pembrolizumab for gastric and GEJ cancers

What is the optimum setting for use of pembrolizumab in gastric and GEJ cancers? Does PD-L1 positivity capture all patients who seem to derive the most benefit from this treatment? While pembrolizumab has shown promising results as second-line treatment for gastric and GEJ adenocarcinomas, the KEYNOTE-061 study did not demonstrate an improvement in OS when used in the second-line setting. Although patients with PD-L1 positivity have better ORR than those with PD-L1-negative tumors, responses – and sometimes CR – are noted in PD-L1-negative patients. While the six-gene interferon γ signature used in KEYNOTE-012 and KEYNOTE-028 did not predict ORR or PFS, a refined 18-gene T-cell inflamed gene expression profiling score used in KEYNOTE-059 showed better predictive potential. The 18 genes included were CCL5, CD27, CD274 [PD-L1], CD-276 [B7-H3], CD8A, CMKLR1, CXCL9, CXCR6, HLA-DQA1, HLA-DRB1, HLA-E, IDO1, LAG3,
A higher aggregate score was noted in responders than in nonresponders to pembrolizumab. Higher scores were significantly associated with improved responses (P=0.01) as well as improved PFS (P=0.002). Although there was a correlation of this score with PD-L1 expression, it was nonlinear. Thus, innovative biomarkers are necessary to identify patients that will best benefit from pembrolizumab therapy. The US FDA approved pembrolizumab for the treatment of patients with MSI-H tumors; however, selecting gastric and esophageal cancer patients based on microsatellite status only is not optimal given the low prevalence and the noted response in MSS patients.

**Ongoing studies with pembrolizumab**

Several clinical trials are currently ongoing with pembrolizumab in combination with other therapy in various settings in gastric and GEJ cancers. Some of them are outlined in Table 4.

**Other immunotherapies and combination treatments**

While several trials are currently ongoing with new checkpoint inhibitors such as durvalumab, atezolizumab, and avelumab, other trials with nivolumab or nivolumab in combination with ipilimumab have shown some promising results.

In the Asian study ATTRACTION-02/ONO-4538-12, patients with metastatic or recurrent gastric or GEJ cancer who had perceived two or more prior lines of treatment were randomized in a 2:1 fashion to nivolumab 3 mg/kg intravenously every 2 weeks or placebo. A total of 493 patients were randomized. The median OS was 5.32 months vs 4.14 months (HR 0.63; 95% CI 0.50–0.78; P<0.0001) favoring nivolumab. Subgroup analyses showed that intestinal histology, having two or more sites of metastatic disease, absence of peritoneal and liver metastases, and having received four or more prior lines of treatment were the groups that benefited the most with nivolumab treatment. The ORR was 31% and OS was superior with nivolumab irrespective of PD-L1 status.

In another study of nivolumab in combination with chemotherapy for treatment-naïve metastatic HER-2-negative gastric/GEJ cancers, 40 patients were randomized to nivolumab 360 mg every 3 weeks plus S-1/oxaliplatin or nivolumab plus capicitabine/oxaliplatin. Both treatments were well tolerated. All patients developed treatment-related AEs. No deaths were reported. The ORR was 68.4%, with 10 patients achieving CR.

In the CheckMate 032 study, patients with metastatic esophageal, GEJ, or gastric cancers who had received one or more prior lines of treatment for metastatic disease were randomized 1:1:1 to nivolumab 3 mg/kg intravenously Q2W (N3) vs nivolumab 1 mg/kg + ipilimumab 3 mg/kg.

**Table 4** Ongoing trials in gastric and gastroesophageal junction cancers with pembrolizumab

<table>
<thead>
<tr>
<th>Study name/ NCT</th>
<th>Phase</th>
<th>Type of treatment</th>
<th>Treatment regimen</th>
<th>Expected N</th>
<th>Study site</th>
<th>Primary endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant/adjuvant perioperative trials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02918162</td>
<td>II</td>
<td>Perioperative</td>
<td>Pembrolizumab + investigator’s choice chemotherapy 3 cycles preoperatively and 3 cycles postoperatively. One additional cycle of pembrolizumab will be given preoperatively. Postoperatively patients will complete 12 months of maintenance therapy</td>
<td>40</td>
<td>USA</td>
<td>24 month DFS</td>
</tr>
<tr>
<td>03064490 (PROCeed)</td>
<td>II</td>
<td>Neoadjuvant</td>
<td>Pembrolizumab × 3 doses preoperatively with concurrent chemoradiation with carboplatin/paclitaxel. Three additional doses of adjuvant pembrolizumab</td>
<td>38</td>
<td>USA</td>
<td>pCR rate</td>
</tr>
<tr>
<td>03488667</td>
<td>II</td>
<td>Perioperative</td>
<td>Pembrolizumab × 3 doses + mFOLFOX × 4 doses preoperatively and pembrolizumab × 12 doses + mFOLFOX × 4 doses postoperatively</td>
<td>40</td>
<td>USA</td>
<td>pCR rate, AEs</td>
</tr>
</tbody>
</table>

(Continued)
Table 4 (Continued)

<table>
<thead>
<tr>
<th>Study name/ NCT</th>
<th>Phase</th>
<th>Type of treatment</th>
<th>Treatment regimen</th>
<th>Expected N</th>
<th>Study site</th>
<th>Primary endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>03221426 (KEYNOTE-585)</td>
<td>III</td>
<td>Perioperative</td>
<td>Cohort 1: pembrolizumab + 5-FU/ cisplatin or capecitabine/cisplatin × 3 doses preoperatively and up to 14 doses postoperatively. Cohort 1 comparator: placebo + 5-FU/cisplatin or capecitabine/cisplatin × 3 doses preoperatively and up to 14 doses postoperatively. Cohort 2: pembrolizumab × 3 doses + FLOT × 4 administrations preoperatively. Pembrolizumab × up to 11 cycles + FLOT × 4 administrations postoperatively. Cohort 2 comparator: placebo × 3 doses + FLOT × 4 administrations preoperatively. Placebo + FLOT × 4 administrations postoperatively.</td>
<td>860</td>
<td>North America, South America, Europe, Russia, Asia</td>
<td>OS, EFS, pCR rate, AEs</td>
</tr>
<tr>
<td>03257163</td>
<td>II</td>
<td>Perioperative in MSI-H or EBV-positive operable gastric cancer</td>
<td>Pembrolizumab × 2 doses → surgery → pembrolizumab + capecitabine × 5 doses → pembrolizumab × up to 11 doses (RT starts at around fourth dose for 5 weeks)</td>
<td>40</td>
<td>USA</td>
<td>RFS</td>
</tr>
<tr>
<td>02730546</td>
<td>Ib/II</td>
<td>Neoadjuvant and adjuvant therapy for operable GEJ and gastric cardia adenocarcinomas</td>
<td>Pembrolizumab plus concurrent chemoradiation with carboplatin/ paclitaxel preoperatively. Pembrolizumab as adjuvant treatment</td>
<td>68</td>
<td>USA</td>
<td>pCR rate, PFS</td>
</tr>
</tbody>
</table>

Metastatic trials – first-line

<table>
<thead>
<tr>
<th>Study name/ NCT</th>
<th>Phase</th>
<th>Type of treatment</th>
<th>Treatment regimen</th>
<th>Expected N</th>
<th>Study site</th>
<th>Primary endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>02494583 (KEYNOTE-062)</td>
<td>III</td>
<td>First-line metastatic (HER-2neu negative, PD-L1 positive)</td>
<td>Pembrolizumab vs placebo + 5-FU + cisplatin</td>
<td>764</td>
<td>Worldwide</td>
<td>PFS, OS</td>
</tr>
<tr>
<td>03342937 (KeyLargo)</td>
<td>II</td>
<td>First-line metastatic</td>
<td>Pembrolizumab + oxaliplatin + capecitabine</td>
<td>50</td>
<td>USA</td>
<td>PFS</td>
</tr>
<tr>
<td>02563548</td>
<td>I</td>
<td>Hyluronan-high NSCLC and gastric cancer. Not have received more than two prior lines of treatment for metastatic gastric cancer</td>
<td>PEGPH20 plus pembrolizumab</td>
<td>81 (including NSCLC)</td>
<td>USA</td>
<td>ORR</td>
</tr>
<tr>
<td>02830594</td>
<td>II</td>
<td>Metastatic esophageal, GEJ and gastric cancers with no limit on number of prior treatments received</td>
<td>Palliative RT for 35 fractions with pembrolizumab</td>
<td>14</td>
<td>USA</td>
<td>Comparison of molecular biomarkers and disease outcomes</td>
</tr>
<tr>
<td>02954536</td>
<td>II</td>
<td>First-line metastatic for HER-2neu positive esophageal, GEJ, or gastric adenocarcinoma</td>
<td>Pembrolizumab + trastuzumab + capecitabine/cisplatin</td>
<td>37</td>
<td>USA</td>
<td>PFS</td>
</tr>
</tbody>
</table>

(Continued)
Q3W × four doses followed by nivolumab 3 mg/kg Q2W (N1 + I3) vs nivolumab 3 mg/kg + ipilimumab 1 mg/kg Q3W × four doses followed by nivolumab 3 mg/kg Q2W (N3 + I1). Seventy nine percent patients had received two or more prior therapies and 24% had PD-L1-positive tumors. The ORRs was 12% (N3), 24% (N1 + I3), and 8% (N3 + I1). The ORRs were 19% (N3), 40% (N1 + I3), 23% (N3 + I1) and 12% (N3), 22% (N1 + I3), 0% (N3 + I1) in PD-L1-positive and PD-L1-negative tumors, respectively. Median OS was 6.2 months (95% CI 3.4–12.4 months) in N3, 6.9 months (95% CI 3.7–11.5 months) in N1 + I3, and 4.8 months (95% CI 3.0–8.4 months) in N3 + I1. Grade 3–4 AEs were noted in more than 10% of each arm. The combination arm showed durable responses in heavily pretreated gastric and GEJ cancers.

Future directions

Checkpoint inhibitors have revolutionized the way we now treat advanced cancers. Several clinical studies have shown some promising response rates even in heavily pretreated population of metastatic gastric and GEJ cancers. However, there yet remains a lack of biomarkers or combination of biomarkers that can help identify patients who will respond to immunotherapy and spare them from serious AEs. It is unclear why pembrolizumab shows the best response rates in third-line setting, while it failed to improve OS when used as a second-line treatment. Ongoing trials will guide us on whether combination treatment with chemotherapy, tyrosine kinase inhibitors, other monoclonal antibodies, or radiation therapy will improve response rates in advanced gastric and GEJ cancers. In addition to pembrolizumab, there are other checkpoint inhibitors that are currently being tested and likely to be approved soon for gastric and GEJ cancers.

Disclosure

The authors report no conflicts of interest in this work.

References


